Bifidobacterium pseudocatenulatum-Mediated Bile Acid Metabolism to Prevent Rheumatoid Arthritis via the Gut–Joint Axis

Early intervention in rheumatoid arthritis (RA) is critical for optimal treatment, but initiation of pharmacotherapy to prevent damage remains unsatisfactory currently. Manipulation of the gut microbiome and microbial metabolites can be effective in protecting against RA. Thus, probiotics can be utilized to explore new strategies for preventing joint damage. The aim of this study was to explore the metabolites and mechanisms by which Bifidobacterium pseudocatenulatum affects RA. Based on 16S rRNA sequencing and UPLC-MS/MS assays, we focused on bile acid (BA) metabolism. In a collagen-induced arthritis (CIA) mouse model, B. pseudocatenulatum prevented joint damage by protecting the intestinal barrier and reshaped gut microbial composition, thereby elevating bile salt hydrolase (BSH) enzyme activity and increasing the levels of unconjugated secondary BAs to suppress aberrant T-helper 1/17-type immune responses; however, these benefits were eliminated by the Takeda G protein-coupled receptor 5 (TGR5) antagonist SBI-115. The results suggested that a single bacterium, B. pseudocatenulatum, can prevent RA, indicating that prophylactic administration of probiotics may be an effective therapy.

[1]  H. Takayanagi,et al.  Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions , 2022, Nature Reviews Rheumatology.

[2]  Jiong Cai,et al.  Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. , 2022, Cell host & microbe.

[3]  Zhaohui Zheng,et al.  TNF antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models , 2022, Nature communications.

[4]  Chaokui Wang,et al.  Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling. , 2021, Cell reports.

[5]  C. Huttenhower,et al.  A Bacterial Bile Acid Metabolite Modulates Treg Activity through the Nuclear Hormone Receptor NR4A1 , 2021, bioRxiv.

[6]  P. Rao,et al.  Potential mechanisms underlying the ameliorative effect of Lactobacillus paracasei FZU103 on the lipid metabolism in hyperlipidemic mice fed a high-fat diet. , 2021, Food research international.

[7]  L. March,et al.  Deficiency of protease-activated receptor (PAR) 1 and PAR2 exacerbates collagen-induced arthritis in mice via differing mechanisms. , 2020, Rheumatology.

[8]  Mark M. Davis,et al.  Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade , 2020, Proceedings of the National Academy of Sciences.

[9]  C. Akdis,et al.  Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection , 2020, EBioMedicine.

[10]  M. L. Fernández-Murga,et al.  Bifidobacterium pseudocatenulatum CECT 7765 reverses the adverse effects of diet-induced obesity through the gut-bone axis. , 2020, Bone.

[11]  H. Min,et al.  Lactobacillus sakei suppresses collagen-induced arthritis and modulates the differentiation of T helper 17 cells and regulatory B cells , 2020, Journal of Translational Medicine.

[12]  Imhoi Koo,et al.  The microbiome modulating activity of bile acids , 2020, Gut microbes.

[13]  G. Xie,et al.  Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism , 2019, Nature Communications.

[14]  Huijue Jia,et al.  A single bacterium restores the microbiome dysbiosis to protect bones from destruction in a rat model of rheumatoid arthritis , 2019, Microbiome.

[15]  Michele Biagioli,et al.  Bile Acids Activated Receptors Regulate Innate Immunity , 2018, Front. Immunol..

[16]  John M. Ashton,et al.  Targeting the gut microbiome to treat the osteoarthritis of obesity. , 2018, JCI insight.

[17]  Mark M. Davis,et al.  Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade , 2017, Proceedings of the National Academy of Sciences.

[18]  F. Turroni,et al.  Glycan Utilization and Cross-Feeding Activities by Bifidobacteria. , 2017, Trends in microbiology.

[19]  Mingyi Chen,et al.  Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine , 2017, Front. Microbiol..

[20]  B. Staels,et al.  Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD. , 2017 .

[21]  Matthias Schneider,et al.  Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort , 2017, BMC Musculoskeletal Disorders.

[22]  H. Mann,et al.  The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis – a cohort study , 2017, Arthritis Research & Therapy.

[23]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[24]  K. Zhao,et al.  Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T cell differentiation , 2014, Nature Communications.

[25]  M. Asghari-Jafarabadi,et al.  Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double‐blind clinical trial , 2014, International journal of rheumatic diseases.

[26]  Y. Belkaid,et al.  Role of the Microbiota in Immunity and Inflammation , 2014, Cell.

[27]  S. Abramson,et al.  Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity , 2014, Current opinion in rheumatology.

[28]  H. Sokol,et al.  Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases , 2012, Gut.

[29]  J. Auwerx,et al.  TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. , 2011, Cell metabolism.

[30]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[31]  Y. Iwamoto,et al.  Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[32]  A. Prieur,et al.  Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. , 1993, Annals of the rheumatic diseases.